Big biotech names roll out Seaport Therapeutics, as interest in neuropsychiatric drugs swells

The team behind Karuna Therapeutics, which was recently snapped up in a multibillion-dollar deal, on Tuesday rolled out another neuropsychiatric-focused biotech, called Seaport Therapeutics. 

The new company will be led by Daphne Zohar, the founding CEO of the biotech startup foundry PureTech Health, which helped launch both Karuna and Seaport. 

Seaport raised $100 million in a Series A round, with backers including the same investors who initially funded Karuna, namely ARCH Venture Partners, Sofinnova Investments, and Third Rock Ventures. 

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In